Merck Spinoff Organon Taps Ex-Allergan Execs Walsh, Stahler for C-Suite

Organon, a company spinning off from Merck (NYSE: MRK), is filling out its C-suite with the appointment of two new executives. Matthew Walsh is joining as chief financial officer; Rachel Stahler as chief information officer. Both come from Allergan, which was recently acquired by AbbVie (NYSE: ABBV). Walsh was Allergan’s executive vice president and CFO while Stahler was CIO.